<DOC>
	<DOCNO>NCT01110499</DOCNO>
	<brief_summary>This study 2 part . Part 1 evaluate safety IOP effect 6 formulation AGN-210961 ophthalmic solution study eye bimatoprost ophthalmic solution 0.03 % fellow eye 7 consecutive day . Part 2 evaluate safety IOP effect formulation ( select part 1 ) AGN-210961 eye compare bimatoprost ophthalmic solution 0.03 % 4 week .</brief_summary>
	<brief_title>Safety Efficacy AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Ocular hypertension primary openangle glaucoma eye Any active ocular disease Anticipated wear contact lens study Anticipated use artificial tear study Contraindication pupil dilatation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>